News and Announcements
SUDA FY16 Update; Several Patents Granted Internationally, Strong IP Portfolio, Operation and Staff Expansion
- Published July 06, 2016 3:05PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SUDA LTD made steady progress with its pipeline of OroMist® oral sprays in FY2016. This included finalising the design of a pivotal PK trial and meeting with the FDA regarding the Company’s SUD-001 sumatriptan oral spray for the treatment of migraine. During the financial year, SUDA was granted several patents in the US, Canada and other territories, strengthening its IP portfolio.
The Company is advancing towards its business development goals to out-license its first-in-class oral sprays to pharmaceutical companies across the world. Discussions with prospective partners span its treatments for malaria, insomnia, migraine, nausea, and erectile dysfunction, as well as the application of SUDA’s OroMist® technology to new compounds.
The Company’s operations have expanded in 2016 with the addition of new staff. SUDA also took full control of its novel sublingual antimalarial ArTiMist™ with the acquisition of the 20% minority shareholding in its subsidiary company, Malaria Research Company Pty Ltd (MRC).
SUDA anticipates that FY2017 will be an exciting year for the Company with the prospect of securing several commercial deals and creating significant shareholder value.
ABOUT SUDA LTD
SUDA Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, WA. The Company is developing low-risk oral sprays using novel formulations of existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums) include ease of use, lower dosage, reduced side effects and faster response time.
SUDA’s product pipeline includes first-in-class oral sprays for insomnia, malaria, migraine, nausea and vomiting, erectile dysfunction and pre-procedural anxiety.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
